Table 2.
Baseline characteristics of OPC patients.
| Characteristics | ALB | |||
|---|---|---|---|---|
| Total, n (%) | ALB< 39.15 (N%) | ALB≥39.15 (N%) | P-value | |
| Total | 246 | 48 | 198 | |
| Albumin (g/L) | ||||
| Mean ± SD | 42.3±4.05 | 36.45±2.82 | 43.74±2.85 | <0.001* |
| Median (IQR) | 42.6 (40.0-45.2) | 36.95 (36.20- 38.30) | 43.40 (41.52- 45.75) | |
| Age (Years) | 0.047* | |||
| ≤65 | 197 (80.1) | 33 (68.8) | 164 (82.8) | |
| >65 | 49 (19.9) | 15 (31.2) | 34 (17.2) | |
| Gender | 0.746 | |||
| Male | 209 (85.0) | 42 (87.5) | 167 (84.3) | |
| Female | 37 (15.0) | 6 (12.5) | 31 (15.7) | |
| Smoking | 0.818 | |||
| Never | 71 (28.9) | 15 (31.2) | 56 (28.3) | |
| Current/former | 175 (71.1) | 33 (68.8) | 142 (71.7) | |
| Alcohol consumption | 0.997 | |||
| Never | 105 (42.7) | 21 (43.8) | 84 (42.4) | |
| Current/former | 141 (57.3) | 27 (56.2) | 114 (57.6) | |
| Presence of comorbidity | 0.009* | |||
| Absent | 141 (57.3) | 19 (39.6) | 122 (61.6) | |
| Present | 105 (42.7) | 29 (60.4) | 76 (38.4) | |
| Charlson score index | 0.007* | |||
| 0 | 175 (71.1) | 26 (54.2) | 149 (75.3) | |
| >1 | 71 (28.9) | 22 (45.8) | 49 (24.7) | |
| PNI | <0.001* | |||
| Mean ± SD | 51.26±5.76 | 43.87±4.22 | 53.05±4.53 | |
| Median (IQR) | 51.75 (47.62-55.05) | 44.62 (44.62-46.34) | 52.58 (50.11-55.60) | |
| TP (g/L) | <0.001* | |||
| Mean ± SD | 72.12±6.89 | 67.72±7.60 | 73.19±6.28 | |
| Median (IQR) | 72.8 (68.90-75.78) | 67.45 (61.98-71.55) | 73.65 (70.22-76.08) | |
| TLC (103/mm3) | <0.001* | |||
| Mean ± SD | 1.79±0.66 | 1.48±0.50 | 1.86±0.68 | |
| Median (IQR) | 1.77 (1.36-2.14) | 1.57 (1.19-1.77) | 1.86 (1.41-2.18) | |
| Hb (g /L) | <0.001* | |||
| Mean ± SD | 143.45±15.85 | 132.94±16.76 | 145.99±14.56 | |
| Median (IQR) | 143.5 (134.0- 154.0) | 137.0 (123.0- 145.2) | 145.0 (136.0- 155.8) | |
| NLR | 0.002* | |||
| Mean ± SD | 2.73±1.58 | 3.36±1.81 | 2.58±1.48 | |
| Median (IQR) | 2.22 (1.70- 3.23) | 3.080 (1.968- 4.242) | 2.17 (1.64- 2.87) | |
| CNC (10 9 /L) | 0.415 | |||
| Mean ± SD | 4.26±1.64 | 4.43±1.81 | 4.21±1.59 | |
| Median (IQR) | 3.97 (3.14- 5.19) | 3.98 (3.19- 5.81) | 3.97 (3.14- 4.81) | |
| AAPR | <0.001* | |||
| Mean ± SD | 0.54±0.17 | 0.43±0.14 | 0.57±0.17 | |
| Median (IQR) | 0.52 (0.43- 0.64) | 0.41 (0.33- 0.50) | 0.5463 (0.46- 0.66) | |
| ALP (U/L) | 0.005* | |||
| Mean ± SD | 84.75±24.07 | 93.44±29.30 | 82.65±22.20 | |
| Median (IQR) | 82.0 (68.0- 98.0) | 89.0 (72.25- 110.25) | 80.0 (68.0- 95.0) | |
| Site (n, %) | 0.096 | |||
| Tonsil | 107 (43.5) | 19 (39.6) | 88 (44.4) | |
| Base of tongue | 85 (34.6) | 13 (27.1) | 72 (36.4) | |
| Soft palate | 54 (22.0) | 16 (33.3) | 38 (19.2) | |
| Disease stage | 0.151 | |||
| I/II | 52 (21.1) | 6 (12.5) | 46 (23.2) | |
| III/IV | 194 (78.9) | 42 (87.5) | 152 (76.8) | |
| T stage | 0.016* | |||
| T1-2 | 162 (65.9) | 24 (50.0) | 138 (69.7) | |
| T3-4 | 84 (34.1) | 24 (50.0) | 60 (30.3) | |
| Lymph nodes status | 0.246 | |||
| Negative(cN1-3) | 76 (30.9) | 11 (22.9) | 65 (32.8) | |
| Positive(cN0) | 170 (69.1) | 37 (77.1) | 133 (67.2) | |
| HPV status | 0.002* | |||
| Positive | 27 (11.0) | 5 (10.4) | 30 (15.2) | |
| Negative | 48 (19.5) | 18 (37.5) | 22 (11.1) | |
| Unknown | 171 (69.5) | 25 (52.1) | 146 (73.7) | |
| Type of therapy | 0.812 | |||
| Surgery | 81 (32.9) | 17 (35.4) | 64 (32.3) | |
| CCRT | 165 (67.1) | 31 (18.8) | 134 (81.2) | |
PNI, prognostic nutritional index; TP, total protein; TLC, total lymphocyte cell; Hb, hemoglobin; NLR, neutrophil to lymphocyte ratio; CNC, circulating neutrophils cell; AAPR, albumin-to-alkaline phosphatase ratio; ALP, alkaline phosphatase; ALB, albumin; CCRT, concurrent chemoradiotherapy; RT, radiation therapy
*Indicates P < 0.05